Pyrin Antibody [L17B15] | Primary Antibodies

Application: Reactivity: Mouse

Lane 1: Bone marrow derived-macrophage of WT C57/B6 mice

Usage Information

Dilution
WB1:1000 IP1:100

Application
WB, IP

Reactivity
Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
86 kDa 110 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Pyrin Antibody [L17B15] detects endogenous levels of total Pyrin protein.

Clone
L17B15

Synonym(s)
MEF, TRIM20, MEFV, Pyrin, Marenostrin

Background
Pyrin is an innate immune sensor encoded by the MEFV gene that belongs to the TRIM family and functions as a cytosolic pattern‑recognition receptor assembling an inflammasome in response to defined disturbances in cytoskeletal and Rho GTPase–dependent homeostasis rather than by directly binding microbial ligands. The protein contains an N‑terminal pyrin domain that mediates homotypic interactions with the adaptor ASC, a central B‑box and coiled‑coil region that support higher‑order assembly and association with cytoskeletal and regulatory partners, and a C‑terminal B30.2/SPRY domain implicated in sensing upstream regulatory changes and in conferring allele‑specific effects on activation threshold. Under resting conditions, RhoA GTPases and their downstream kinases PKN1 and PKN2 phosphorylate pyrin at specific serine residues, creating docking sites for 14‑3‑3 proteins that maintain pyrin in an inactive state, so that intact RhoA signaling keeps the pyrin inflammasome off despite the presence of MEFV. Bacterial toxins and effectors that inactivate RhoA or otherwise disrupt its signaling relieve this repression by preventing pyrin phosphorylation and 14‑3‑3 binding, which permits pyrin oligomerization, ASC recruitment via pyrin–PYD to ASC–PYD interactions, and subsequent recruitment and proximity‑induced activation of pro‑caspase‑1. Activated caspase‑1 cleaves pro–IL‑1β and pro–IL‑18 into their mature forms and processes gasdermin D to drive pyroptotic cell death, thereby coupling detection of pathogen‑induced RhoA inactivation to rapid release of key pro‑inflammatory cytokines and lytic elimination of the infected cell. Pyrin is expressed at high levels in neutrophils, monocytes, and macrophages and contributes to host defense against pathogens that target Rho GTPases, with pyrin‑dependent inflammasome activation lowering bacterial loads and shaping inflammatory responses in lung, gut, and systemic infection models. Missense and truncating mutations in MEFV, particularly within the B30.2 domain, lower the activation threshold or disrupt negative regulation of pyrin, resulting in constitutive or exaggerated inflammasome assembly, increased caspase‑1 activity, and excessive IL‑1β/IL‑18 production that underlie familial Mediterranean fever and other pyrin‑associated autoinflammatory diseases.

Background

Pyrin is an innate immune sensor encoded by the MEFV gene that belongs to the TRIM family and functions as a cytosolic pattern‑recognition receptor assembling an inflammasome in response to defined disturbances in cytoskeletal and Rho GTPase–dependent homeostasis rather than by directly binding microbial ligands. The protein contains an N‑terminal pyrin domain that mediates homotypic interactions with the adaptor ASC, a central B‑box and coiled‑coil region that support higher‑order assembly and association with cytoskeletal and regulatory partners, and a C‑terminal B30.2/SPRY domain implicated in sensing upstream regulatory changes and in conferring allele‑specific effects on activation threshold. Under resting conditions, RhoA GTPases and their downstream kinases PKN1 and PKN2 phosphorylate pyrin at specific serine residues, creating docking sites for 14‑3‑3 proteins that maintain pyrin in an inactive state, so that intact RhoA signaling keeps the pyrin inflammasome off despite the presence of MEFV. Bacterial toxins and effectors that inactivate RhoA or otherwise disrupt its signaling relieve this repression by preventing pyrin phosphorylation and 14‑3‑3 binding, which permits pyrin oligomerization, ASC recruitment via pyrin–PYD to ASC–PYD interactions, and subsequent recruitment and proximity‑induced activation of pro‑caspase‑1. Activated caspase‑1 cleaves pro–IL‑1β and pro–IL‑18 into their mature forms and processes gasdermin D to drive pyroptotic cell death, thereby coupling detection of pathogen‑induced RhoA inactivation to rapid release of key pro‑inflammatory cytokines and lytic elimination of the infected cell. Pyrin is expressed at high levels in neutrophils, monocytes, and macrophages and contributes to host defense against pathogens that target Rho GTPases, with pyrin‑dependent inflammasome activation lowering bacterial loads and shaping inflammatory responses in lung, gut, and systemic infection models. Missense and truncating mutations in MEFV, particularly within the B30.2 domain, lower the activation threshold or disrupt negative regulation of pyrin, resulting in constitutive or exaggerated inflammasome assembly, increased caspase‑1 activity, and excessive IL‑1β/IL‑18 production that underlie familial Mediterranean fever and other pyrin‑associated autoinflammatory diseases.

References
https://pubmed.ncbi.nlm.nih.gov/31456795/ https://pubmed.ncbi.nlm.nih.gov/27066000/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%